Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer Journal Article
| Authors: | Han, J.; Zakeri, K.; Raab, G.; Hesse, J.; Shamseddine, A.; Chen, L.; Yu, Y.; Kang, J. J.; McBride, S. M.; Riaz, N.; Tsai, C. J.; Gelblum, D.; Sherman, E. J.; Wong, R. J.; Michel, L.; Lee, N. Y. |
| Article Title: | Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer |
| Abstract: | Background: We report the outcomes of cisplatin-ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel. Materials and Methods: We included consecutive HNSCC patients treated from 2013 to 2021 that received definitive chemoradiation with carboplatin and paclitaxel. Locoregional recurrences (LRR) and distant metastases (DM) were estimated using cumulative incidence functions. Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier methods. Results: Sixty-five patients were identified with median age of 71 years (range 44–85). Median radiation dose was 70 Gy and the median doses of carboplatin and paclitaxel were AUC 1 and 40 mg/m2, respectively. At a median follow-up of 29 (range 5–91) months, the 2-year rates of LRR, DM, PFS, and OS were 8.8%, 9.4%, 72.2%, and 88.7%, respectively. In total, there were 5 LRR, 7 DM, and 12 deaths. Conclusions: Chemoradiation with carboplatin and paclitaxel is an excellent option for cisplatin-ineligible HNSCC patients. © 2023 Wiley Periodicals LLC. |
| Keywords: | adult; cancer survival; treatment outcome; aged; aged, 80 and over; middle aged; survival rate; major clinical study; overall survival; constipation; cancer localization; cancer recurrence; cisplatin; advanced cancer; cancer combination chemotherapy; paclitaxel; follow up; antineoplastic agent; cancer incidence; carboplatin; progression free survival; quality of life; multiple cycle treatment; neoplasm recurrence, local; mucosa inflammation; antineoplastic combined chemotherapy protocols; radiotherapy dosage; cohort analysis; cancer mortality; distant metastasis; febrile neutropenia; dysphagia; survival time; head and neck neoplasms; tumor recurrence; cancer of unknown primary site; head and neck tumor; locally advanced head and neck cancer; chemoradiotherapy; narcotic agent; cumulative incidence; head and neck squamous cell carcinoma; very elderly; humans; human; male; female; article; larynx squamous cell carcinoma; hypopharynx squamous cell carcinoma; oropharynx squamous cell carcinoma; squamous cell carcinoma of head and neck; cisplatin ineligible; concurrent carboplatin and paclitaxel; older age and comorbidities |
| Journal Title: | Head & Neck |
| Volume: | 45 |
| Issue: | 9 |
| ISSN: | 1043-3074 |
| Publisher: | John Wiley & Sons, Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | 2207 |
| End Page: | 2216 |
| Language: | English |
| DOI: | 10.1002/hed.27456 |
| PUBMED: | 37439286 |
| PROVIDER: | scopus |
| PMCID: | PMC10981461 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
